Pfizer's Xalkori rides on in first-line NSCLC | PharmaBoardroom
written on 26.03.2014
Tags:
,

Pfizer's Xalkori rides on in first-line NSCLC

TAGS: ,

Pfizer is now poised to tout its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) as a standard of care in both the first and second-line setting for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC), following…

Latest Report